Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates

Company Performance - Aprea Therapeutics reported a quarterly loss of $0.58 per share, better than the Zacks Consensus Estimate of a loss of $0.64, and an improvement from a loss of $0.87 per share a year ago, indicating a 33.33% year-over-year improvement [1] - The company achieved a revenue of $0.56 million for the quarter, surpassing the Zacks Consensus Estimate by 462%, compared to $0.25 million in the same quarter last year [1] - Over the last four quarters, Aprea Therapeutics has exceeded consensus EPS estimates three times and topped consensus revenue estimates two times [1] Market Outlook - Aprea Therapeutics shares have declined approximately 28.5% since the beginning of the year, contrasting with the S&P 500's gain of 12% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.65 on revenues of $0.15 million, and for the current fiscal year, it is -$2.57 on revenues of $0.8 million [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Aprea Therapeutics belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [5] - Precigen, Inc., another company in the same industry, is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of -12.5%, with revenues anticipated to be $1.28 million, down 27.7% from the previous year [5][6]